EVALUATION OF TROUGH LEVEL AND DISEASE ACTIVITY AFTER SWITCH FROM ADALIMUMAB ORIGINATOR TO BIOSIMILAR IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Nele Deprez  ¹     Thomas De Somer     Didier Baert     Mieke Deceuninck  ²     Inge Huys     Veerle Mattens  ³     An Sterckx     Stijn Vanden Branden     Erik Vanderstraeten     Jo Vandervoort     Nina Van Heddegem     Pieter Dewint    
¹ AZ Maria Middelares Gent, Gent, Belgium
² Sint Vincentius Ziekenhuis Deinze, Deinze, Belgium
³ OLV Ziekenhuis Aalst, Aalst, Belgium

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)